Maxwell Wealth Strategies Inc. Has $2.74 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Maxwell Wealth Strategies Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,570 shares of the medical research company's stock after buying an additional 3,145 shares during the quarter. IQVIA accounts for about 1.2% of Maxwell Wealth Strategies Inc.'s portfolio, making the stock its 26th largest position. Maxwell Wealth Strategies Inc.'s holdings in IQVIA were worth $2,742,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA during the second quarter worth about $27,000. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the 3rd quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA during the 2nd quarter worth approximately $29,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV traded down $10.26 during midday trading on Friday, hitting $192.68. 4,579,136 shares of the company's stock were exchanged, compared to its average volume of 1,143,450. The company's 50 day moving average price is $226.95 and its 200 day moving average price is $228.29. IQVIA Holdings Inc. has a 12 month low of $189.63 and a 12 month high of $261.73. The firm has a market capitalization of $34.97 billion, a PE ratio of 25.28, a price-to-earnings-growth ratio of 2.17 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. BTIG Research reduced their price target on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a report on Friday, November 1st. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Friday, November 8th. UBS Group upped their price objective on IQVIA from $295.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, July 23rd. Robert W. Baird cut their target price on IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research note on Friday, November 1st. Finally, Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $259.13.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.